Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01861054
Recruitment Status : Terminated (Enrollment target not reached)
First Posted : May 23, 2013
Last Update Posted : October 18, 2017
Information provided by (Responsible Party):
Dompé Farmaceutici S.p.A

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Primary Completion Date : March 2015
  Study Completion Date : March 1, 2016